These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20622200)

  • 1. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants.
    Bavisotto LM; Ellis DJ; Milner PG; Combs DL; Irwin I; Canafax DM
    J Clin Pharmacol; 2011 Apr; 51(4):561-74. PubMed ID: 20622200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.
    Choppin A; Irwin I; Lach L; McDonald MG; Rettie AE; Shao L; Becker C; Palme MP; Paliard X; Bowersox S; Dennis DM; Druzgala P
    Br J Pharmacol; 2009 Nov; 158(6):1536-47. PubMed ID: 19845677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.
    Albrecht D; Turakhia MP; Ries D; Marbury T; Smith W; Dillon D; Milner PG; Midei MG
    Thromb Haemost; 2017 Nov; 117(11):2026-2033. PubMed ID: 28933798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant.
    Albrecht D; Ellis D; Canafax DM; Combs D; Druzgala P; Milner PG; Midei MG
    Thromb Haemost; 2017 Apr; 117(4):706-717. PubMed ID: 28180234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.
    Whitlock RP; Fordyce CB; Midei MG; Ellis D; Garcia D; Weitz JI; Canafax DM; Albrecht D; Milner PG
    Thromb Haemost; 2016 Aug; 116(2):241-50. PubMed ID: 27173100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.
    Ellis DJ; Usman MH; Milner PG; Canafax DM; Ezekowitz MD
    Circulation; 2009 Sep; 120(12):1029-35, 2 p following 1035. PubMed ID: 19738136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
    Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
    Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.
    Fang ZZ; Zhang YY; Ge GB; Huo H; Liang SC; Yang L
    Br J Clin Pharmacol; 2010 Feb; 69(2):193-9. PubMed ID: 20233183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers.
    Hegazy SK; Mabrouk MM; Elsisi AE; Mansour NO
    Eur J Clin Pharmacol; 2012 Sep; 68(9):1275-80. PubMed ID: 22392555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors.
    Zhu YT; Teng Z; Zhang YF; Li W; Guo LX; Liu YP; Qu XJ; Wang QR; Mao SY; Chen XY; Zhong DF
    Drug Des Devel Ther; 2020; 14():1963-1970. PubMed ID: 32546963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
    Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
    Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition.
    Neal JM; Kunze KL; Levy RH; O'Reilly RA; Trager WF
    Drug Metab Dispos; 2003 Aug; 31(8):1043-8. PubMed ID: 12867493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
    Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
    Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models.
    Bowersox SS; Canafax D; Druzgala P; Milner P; Weitz JI
    Thromb Res; 2010 Nov; 126(5):e383-8. PubMed ID: 20869102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M
    Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential genotype dependent inhibition of CYP2C9 in humans.
    Kumar V; Brundage RC; Oetting WS; Leppik IE; Tracy TS
    Drug Metab Dispos; 2008 Jul; 36(7):1242-8. PubMed ID: 18378563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voriconazole and fluconazole increase the exposure to oral diazepam.
    Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial.
    Zhou Q; Wang Z; Wang H; Chen Z; Li X; Dai X; Zhang Y; Yu X; Zhou R; Hu W
    Am J Cardiovasc Drugs; 2023 Jan; 23(1):101-112. PubMed ID: 36622539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction.
    Kunze KL; Trager WF
    Drug Metab Dispos; 1996 Apr; 24(4):429-35. PubMed ID: 8801058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.